The Wegovy Pill's Fast Start in 2026: What New Data on 148,000 Patients Says About Pills vs. Injections

Researchers analyzed de-identified electronic health records from Epic Cosmos, a database covering more than 300 million patient records across 2,000+ hospitals and 47,100 clinics, as reported by AJMC. They followed 47.9 million US adults who met eligibility criteria for obesity medication (a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, excluding those with type 2 diabetes) from December 22, 2025 through March 15, 2026 — the pill's first 12 weeks on the market.

In that window, 148,792 adults started oral semaglutide, compared with 227,040 who started injectable semaglutide (Wegovy shots) and 355,513 who started injectable tirzepatide (Zepbound). Weekly new starts of the pill climbed from essentially zero to a peak of 4.56 per 10,000 eligible adults by week 10 — at which point the pill briefly overtook injectable semaglutide. The vast majority of oral initiators (87.6%) received the new oral Wegovy rather than the older, lower-dose Rybelsus.

One number stands out: tirzepatide injections remained the most-started obesity medication throughout the entire study period. The pill is growing fast, but injections — especially tirzepatide — are still where most patients land.

About 53% of the people starting oral semaglutide had never used a GLP-1 before. The rest were switchers: 28.9% had previously used injectable semaglutide and 27.5% had used tirzepatide in the prior year.

Compared with patients starting injections, pill starters were older (average age 53.3 versus about 50), more often women (72.7%), had somewhat lower starting BMIs (36.6 versus around 38), and were more likely to be on Medicare. Physician's Weekly notes that roughly half of all initiating prescriptions came from family medicine clinicians — meaning this is increasingly an everyday primary-care conversation, not a specialty one.

The pattern makes intuitive sense. A daily tablet appeals to people with needle hesitancy, people who travel often, and people with less weight to lose who want a gentler entry point into treatment.

Convenience is only half the decision. In the 64-week OASIS 4 trial, participants who stayed on the 25 mg oral semaglutide dose lost an average of 16.6% of their body weight — a strong result, broadly in line with injectable semaglutide.

Tirzepatide, however, still sets the bar. In the head-to-head SURMOUNT-5 trial, Eli Lilly reported that Zepbound produced an average weight loss of 20.2% versus 13.7% for injectable Wegovy over 72 weeks. That gap is one reason tirzepatide kept the top spot in the new uptake data even as the pill surged. If maximizing total weight loss is the priority — particularly at higher starting weights — a tirzepatide-based treatment plan like JoeyMed's compounded tirzepatide program remains the strongest-performing option available through telehealth today.

There's also a practical wrinkle with the pill: it must be taken on an empty stomach with a small amount of water, waiting before eating — every single day. Some patients find a once-weekly injection easier to stay consistent with than a daily routine with food-timing rules. Adherence, not the molecule, is often what determines real-world results.

The authors were careful about limits. The data captures prescriptions written, not necessarily filled or taken. It likely misses prescriptions from direct-to-consumer telehealth platforms outside participating health systems — so true uptake may be even higher. And 12 weeks says nothing about persistence: whether pill starters stay on therapy, tolerate it, and keep weight off over a year or more is the question the next round of studies needs to answer.

Side effects are a real part of that equation. Oral and injectable semaglutide share the familiar GLP-1 profile — nausea, vomiting, constipation, and diarrhea, especially during dose escalation. Managing those early weeks well (slow titration, hydration, smaller meals, and anti-nausea support when needed) is often the difference between quitting and succeeding. GLP-1s also aren't right for everyone: they're not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, during pregnancy, or with a history of pancreatitis — which is why screening by a licensed provider matters before any prescription.

The real takeaway from this study isn't that pills are beating injections — it's that patients finally have genuine options, and the right one depends on your weight loss goals, your health history, your tolerance for daily routines versus weekly shots, and your budget. That's a conversation, not a coin flip.

JoeyMed's licensed providers have that conversation with you. Start with a free online visit at joeymed.com/weight-loss, share your health history, and a provider will help you decide whether a tirzepatide-based plan, a semaglutide-based plan, or another approach fits you best — with ongoing check-ins, dose adjustments, and side effect support included. If medication is appropriate, treatment ships discreetly to your door, and your care team stays with you for the long haul — because as this new data reminds us, starting a medication is the easy part. Staying on the right one is where results come from.